Introduction
The therapeutic value of fenclofenac in rheumatoid arthritis was assessed in two separate studies. Initially its general effectiveness was compared with placebo, and subsequently the relief of symptoms at night and in the morning obtained from an evening dose of fenclofenac was compared with indomethacin suppositories. The results of both these double-blind cross-over trials are reported below.
Patients and Methods Twenty patients with classical or definite rheumatoid arthritis volunteered for each trial and their informed consent was obtained. No patient participated in both trials. Patients were included only if they required an improvement in their current anti-rheumatic therapy. However, the following were excluded: patients with a history of peptic ulceration, chronic gastrointestinal symptoms, significant hepatic or renal disease, or any ocular condition currently under therapy; pregnant women, or those likely to become pregnant; and patients receiving gold, corticosteroids, penicillamine, immunosuppressives or anti-coagulant treatment. In addition, in the study comparing fenclofenac with indomethacin suppositories, patients were excluded if they were receiving indomethacin or phenylbutazone or had a known sensitivity to aspirin, indomethacin or fenclofenac or a recent history of proctitis.
First Study -Double-blind Comparison of Fenclofenac versus Placebo
In this study a pre-treatment period was instituted, during which all anti-rheumatic drugs were stopped for three days. Paracetamol tablets were given for the run-in period, and as a rescue drug. Subsequently fenclofenac 300 mg each morning and 600 mg at night, or matching placebo tablets, were given for periods of two weeks in random allocation and under double-blind conditions. This was followed by a cross-over to the alternative treatment for a further two-week period. Assessments were carried out at the end of the run-in period and at the end of each fortnight. These included the patient's assessment of the overall pain level on a 10 cm visual analogue scale, duration of morning stiffness in minutes, articular index (Ritchie et al. 1968 ), grip strength in each hand, taken as the best of three readings with the sphygmomanometer bag at 30 mmHg, the range of movement in four affected joints measured with a pendulum goniometer, the patient's overall assessment of progress and the recording of adverse effects and the reason for any withdrawal from the study. Laboratory assessment included a full blood count and ESR, blood urea and uric acid, liver function tests and urinalysis. Plasma levels of fenclofenac were determined. Patients were asked which of the two drug periods they preferred and how the better of the two fortnights compared with their regular anti-rheumatic medication.
Results
Of the 20 patients who entered this study, 13 completed both fortnights of drug administration and their results could be fully analysed. Four other patients, who withdrew during the course of the second fortnight, could still express a drug 
, binomial test * Since the patients did not all have the same joint affected, each joint was considered separately and therefore it is inappropriate to quote mean values preference. Sixteen of these 17 patients preferred fenclofenac to the placebo (P<0.01). Of these 16 patients, 5 thought that fenclofenac was better than their previous medication, which included ibuprofen, aspirin and indomethacin. A further 3 patients thought that fenclofenac was equally as effective as their previous medication, which included aspirin, indomethacin and phenylbutazone. Two patients thought that fenclofenac was not as good as indomethacin which they had previously taken. Fenclofenac was significantly better than placebo in the relief of pain (P<0.001), in the reduction of the articular index (P<0.05), in the improvement of grip strength (P<0.01 right, P<0.05 left) and in the reduction of the duration of morning stiffness (P<0.05). There was a significant increase in the range of motion of the four affected joints which were measured (P<0.05) ( Table 1) . During fenclofenac medication, 2 patients developed a macular, itchy rash and medication was stopped for both. Four patients developed nausea and indigestion, requiring withdrawal of medication in 2 cases. One patient with asthma, not requiring treatment at the time, noticed an increase in bronchospasm but it was not severe enough to discontinue medication. While on placebo, 2 patients experienced an intolerable increase of their symptoms and had to be withdrawn from the trial. One patient developed a macular itchy rash and was also withdrawn. Two patients experienced mild nausea and indigestion (Table 2) . Although statistically significant changes were detected in some of the laboratory Table 2 Unwanted effects and reasons for withdrawal from the placebo study Table 3 parameters which were assessed during the study, this was not felt to be of clinical significance (Table 3) .
In every patient analysed while on fenclofenac, plasma levels of this drug were within the therapeutic range previously established, and no other anti-inflammatory drugs were detected. Patient compliance was thus shown to be excellent.
Second Study -Comparison ofFenclofenac versus Indomethacin Suppositories
In the second study, comparing fenclofenac with indomethacin suppositories, a double-dummy technique was used to ensure double-blind conditions. Each night, either fenclofenac 900 mg plus a placebo suppository or an Indocid suppository 100 mg plus placebo tablets were taken by the patients in random allocation for one week in addition to their usual anti-inflammatory medication. A cross-over was then made to the alternative treatment for a further week. Assessments were carried out initially and at the end of each week, and included duration of morning stiffness in minutes, the patient's assessments (on 10 cm visual analogue scales) of degree of morning stiffness, night pain and quality of sleep. Adverse effects and the reasons for any withdrawal from the trial were recorded. At the conclusion of the trial patients were asked which week's medication they had preferred.
Results
Of the 20 patients who entered this study 16 successfully completed both treatment periods. Four patients were either withdrawn or transferred prematurely to the alternative therapy, but all patients were able to state whether they preferred either treatment period. Nine patients preferred the fenclofenac period, 8 preferred the indomethacin period and 3 had no preference. There was therefore no statistically significant difference in patient preference for either drug. Each treatment resulted in a statistically significant improvement in the severity and duration of morning stiffness and quality of sleep compared with base-line values but there were no significant differences observed between treatments. Thus both treatments were shown to be equally effective in relieving the symptoms of stiffness and night pain (Table 4) .
One patient compained of pain and insomnia during the fenclofenac period and was transferred after four days to indomethacin but she had to be withdrawn after a further four days for the same reason. A second patient reported no benefit from fenclofenac. Her right hand was swollen and weak and she complained of loss of appetite and generally felt ill. She was transferred after three days to indomethacin but had to be withdrawn after one day because of light-headedness. Two further patients had to be withdrawn or prematurely transferred during the indomethacin period; one patient because of pruritus; the other because of attacks of migraine. Both of these patients successfully tolerated fenclofenac ( Table 5 ). The remaining side-effects reported were mild and should not be ascribed necessarily to either trial medication since the patients were all receiving additional anti-inflammatory medication during the course of the study. However, it is of interest that 8 patients complained of loose bowels, diarrhoea or urgency to defecate which may have been related to the use of the suppository.
Discussion
Fenclofenac has been shown to be an effective treatment for the relief of the symptoms of rheumatoid arthritis. The results of the placebocontrolled study indicated that it exerted a marked effect on pain, stiffness and inflammation and increased the range of joint movement. The variety and severity of side-effects encountered in this trial were comparable to those expected from other anti-inflammatory agents. Fenclofenac has a plasma half-life of 12-24 hours in man and because of this long duration of action it was supposed that it might be particularly effective in controlling night pain and early morning stiffness. This supposition was confirmed in the second study in which a single dose of 900 mg fenclofenac taken in the evening was shown to be as effective as a 100 mg indomethacin suppository. Thus fenclofenac should be suitable for those patients who have severe night pain and early morning stiffness.
The combined results of the studies suggest that fenclofenac is an effective anti-inflammatory/ analgesic agent which should prove to be a useful treatment for rheumatoid arthritis. Further studies are now required to define fully its value in the long-term management of this disease.
